Furthermore, because clinical criteria for Alzheimer’s disease have limited sensitivity and specificity for Alzheimer’s disease pathology,9 the addition of plasma-based biomarkers of phosphorylated tau to clinical workups may provide information to physicians evaluating individuals with age-related cognitive impairment.10 Here, MAPT is linked to early-onset autosomal dominant Alzheimer disease.